Ruben Blachman-Braun

Jul 11, 2024 | digitalcommons.library.tmc.edu | Kunal Jain |Ruben Blachman-Braun |Esha Jain |Amanda Eng

INTRODUCTION: Ureteroscopy (URS) is commonly performed under general anesthesia (GA) to maximize patient tolerability and minimize surgical complications; however, given the improvements in endoscopic technology and risks associated with GA, alternate forms of anesthesia have been postulated. We aimed to evaluate the outcomes of URS under conscious sedation. METHODS: We completed a retrospective cohort study from November 2019 to June 2020 at a tertiary-level hospital.

May 1, 2024 | auajournals.org | Yuval Avda |Ruben Blachman-Braun |Bruno Nahar |Sabika Sadiq

INTRODUCTION AND OBJECTIVE: Bladder sarcomas are a rare group of malignancies, with most of the data published comprised mostly of single center cohorts. This National Cancer Data Base (NCDB) is a national hospital-based registry, that includes more the 1,500 sites. In this study we used the NCDB to explore bladder sarcomas in the United States, utilizing the database advantages of its size, breadth, and inclusion of treatments given, as well as survival.

Aug 25, 2023 | nature.com | Ruben Blachman-Braun |Dhiraj S. Bal

AbstractCollagenase Clostridium histolyticum (CCh), the first approved non-surgical treatment for Peyronie’s disease (PD), was withdrawn from the European, Canadian, and Asian markets due to poor demand and lack of government reimbursement options. We sought to assess insurance approval rates and usage of CCh across Canada to understand the factors that led to its withdrawal.